Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials

Related

• 

  Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting

  Marko Lukic, MD PhD FEBO FASRS

  On Demand Cases, Courses, and Papers

  2019

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Diabetic Retinopathy and the MyVisionTrack App Study (DRAMA)

  Samuel K. Steven Houston, MD, FASRS

  On Demand Cases, Courses, and Papers

  2017